VistaGen Therapeutics Q3 EPS $(0.45) Misses $(0.44) Estimate, Sales $303.000K Miss $366.000K Estimate
Benzinga Newsdesk 9 months ago
EarningsEarnings MissesNews
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.44) by 2.74 percent. This is a 2.17 percent increase over losses of $(0.46) per share
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.44) by 2.74 percent. This is a 2.17 percent increase over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $303.000 thousand which missed the analyst consensus estimate of $366.000 thousand by 17.21 percent. This is a 29.49 percent increase over sales of $234.000 thousand the same period last year.